The company is actively advancing its lead asset onvansertib through Phase 2 trials with positive clinical data, securing funding through a $10 million registered direct offering, and presenting at major industry conferences. These activities indicate progress in drug development and investor confidence in the pipeline.
The company announced successful Phase 2 trial results with dose-dependent improvements in clinical endpoints (overall response rate and progression-free survival), completed a successful End-of-Phase 2 FDA meeting, and is advancing onvansertib into a registrational Phase 3 trial. These represent significant clinical and regulatory progress for the lead asset.
The company is presenting updated clinical trial data at a major oncology conference (ASCO), which indicates progress in drug development. The selection for a rapid oral presentation (rather than poster) suggests meaningful results. The expansion of onvansertib evaluation across multiple cancer types (pancreatic, lung, breast, leukemia) demonstrates broad therapeutic potential and clinical momentum.
The company announced positive preclinical data demonstrating enhanced antitumor activity and reversal of resistance with its lead candidate onvansertib in combination therapy. This represents progress in expanding the drug's potential applications beyond its primary indication, supporting the company's pipeline development strategy.
Articles that tag CRDF but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
